Jason Lettmann joined Morgenthaler in 2009 and is a Principal on the Life Science Team. Jason is based in Palo Alto, CA, and invests in the life science and medical device sectors. He serves on the Board of Relievant Medsystems, Second Genome and Vapotherm, is a co-founder and on the Board of Tarsus Medical, and is a Board observer at Ardian (acquired by Medtronic), Cabochon Aesthetics, The Foundry and Moximed.
Before joining Morgenthaler, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was actively involved with the founding of Zyga Technologies as well as with several start-ups founded at ForSight Labs and the Foundry incubators. He also was involved with the firm’s investments in Evalve (acquired by Abbott Labs), Entellus Medical, EBR Systems, Mirabilis and Miramar Labs.
Prior to Split Rock, Jason’s experience includes tenure with Guidant Corporation’s Compass Group which focused on corporate venture and business development as well as a consultant with Accenture’s Health and Life Science practice where he advised clients across the medical device, pharmaceutical and health payer sectors. Jason also previously worked as a genetic research analyst at the University of Iowa Hospitals and Clinics.
Jason holds an M.B.A. with distinction from the University of Michigan’s Ross School of Business and a B.A. with honors from the University of Iowa.
- Relievant Medsystems
- Second Genome
- Tarsus Medical
Life Sciences/Medical Devices
- The Human Microbiome Gets A Big Pharma Investment
- Second Genome Closes Series A With $11.5M
- Vapotherm Closes $29 Mln Round
- Relievant Medsystems Announces $30 Million Series D Financing
- Relievant Medsystems Receives FDA Approval to Begin Pivotal Study
- Second Genome Raises $5M Series A To Map Microbes
- Second Genome Announces Series A Financing